Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
SEAGEN INC COM
(NASDAQ:SGEN)
Intraday
Get Report
Watch
Perks
Buy
Compare Brokers
Last update: 7:00PM
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for SEAGEN INC COM Stock (NASDAQ:SGEN)
SEAGEN INC COM Stock (NASDAQ: SGEN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, February 22, 2024
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Upwallstreet
-
Feb 22, 2024, 12:21PM
Tuesday, January 02, 2024
How To Earn $500 A Month From Pfizer Stock
Avi Kapoor
-
Jan 2, 2024, 7:59AM
Friday, December 29, 2023
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
Vandana Singh
-
Dec 29, 2023, 7:04AM
Wednesday, December 20, 2023
Pharma Continues Its Ongoing Battle Against Cancer
Upwallstreet
-
Dec 20, 2023, 12:13PM
Saturday, December 16, 2023
FDA Approves Expanded Indication For KEYTRUDA Plus Padcev For The First-Line Treatment Of Adult Patients With Locally Advanced Or Metastatic Urothelial Cancer
Happy Mohamed
-
Dec 16, 2023, 6:38PM
Thursday, December 14, 2023
Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast
Nabaparna Bhattacharya
-
Dec 14, 2023, 1:34PM
Pfizer Says It Completed Acquisition of Seagen; Deal Completed At $229 In Cash Per Share Of Seagen For a Total Enterprise Value Of Approximately $43B
Benzinga Newsdesk
-
Dec 14, 2023, 7:42AM
Wednesday, December 13, 2023
Looking Into Seagen's Recent Short Interest
Benzinga Insights
-
Dec 13, 2023, 3:30PM
Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'
Avi Kapoor
-
Dec 13, 2023, 8:21AM
Why Is US Pharma Giant Pfizer Stock Trading Lower Today?
Vandana Singh
-
Dec 13, 2023, 7:50AM
Tuesday, December 12, 2023
Seagen shares are trading higher after Pfizer announced it has received all required regulatory approvals to complete the acquisition of the company.
Benzinga Newsdesk
-
Dec 12, 2023, 2:30PM
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
Vandana Singh
-
Dec 12, 2023, 1:03PM
Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune
Vandana Singh
-
Dec 12, 2023, 9:00AM
Monday, December 11, 2023
What the Options Market Tells Us About Seagen
Benzinga Insights
-
Dec 11, 2023, 2:01PM
Seagen's ADCETRIS® Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients With Early Stage Classical Hodgkin Lymphoma
Benzinga Newsdesk
-
Dec 11, 2023, 2:14AM
Friday, December 08, 2023
A Closer Look at Seagen's Options Market Dynamics
Benzinga Insights
-
Dec 8, 2023, 2:31PM
Thursday, December 07, 2023
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
-
Dec 7, 2023, 12:00PM
Wednesday, December 06, 2023
TUKYSA In Combination With Antibody-Drug Conjugate Ado-Trastuzumab Emtansine Improves Progression-Free Survival In Patients With Previously Treated HER2-Positive Metastatic Breast Cancer
Benzinga Newsdesk
-
Dec 6, 2023, 8:19AM
Thursday, November 30, 2023
Seagen Says FDA Grants Priority Review For Supplemental Biologics License Application (sBLA) Of PADCEV (enfortumab vedotin-ejfv) With KEYTRUDA (pembrolizumab) For First-Line Treatment Of Advanced Bladder Cancer
Benzinga Newsdesk
-
Nov 30, 2023, 5:03PM
Monday, November 20, 2023
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today
Benzinga Insights
-
Nov 20, 2023, 4:30PM
Friday, November 10, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Nov 10, 2023, 12:35PM
Monday, November 06, 2023
This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play'
Lisa Levin
-
Nov 6, 2023, 9:37AM
Friday, November 03, 2023
Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years
Benzinga Insights
-
Nov 3, 2023, 1:30PM
Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting
Benzinga Newsdesk
-
Nov 3, 2023, 12:12PM
Thursday, November 02, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Nov 2, 2023, 1:35PM
Seagen Inc. Announces New Data For ADCETRIS With Immunotherapy Combination In Hodgkin Lymphoma To Be Featured At 2023 ASH Annual Meeting, And Seagen To Unveil Novel CD30-Directed Antibody-Drug Conjugate
Benzinga Newsdesk
-
Nov 2, 2023, 1:01PM
Wednesday, November 01, 2023
Looking At Seagen's Recent Unusual Options Activity
Benzinga Insights
-
Nov 1, 2023, 1:46PM
Seagen's Proposed Pfizer Transaction On-Track And Anticipated To Close In Late-2023 or Early-2024, Subject to Closing Conditions, With Ongoing FTC Review and Recent European Commission Approval
Benzinga Newsdesk
-
Nov 1, 2023, 8:03AM
Seagen Q3 EPS $(1.15) Misses $(0.79) Estimate, Sales $648.65M Beat $635.08M Estimate
Benzinga Newsdesk
-
Nov 1, 2023, 8:01AM
Earnings Scheduled For November 1, 2023
Benzinga Insights
-
Nov 1, 2023, 7:19AM
Tuesday, October 31, 2023
Earnings Outlook For Seagen
Benzinga Insights
-
Oct 31, 2023, 5:01PM
Wednesday, October 25, 2023
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Oct 25, 2023, 1:35PM
Monday, October 23, 2023
(SGEN) - Analyzing Seagen's Short Interest
Benzinga Insights
-
Oct 23, 2023, 4:15PM
Sunday, October 22, 2023
Seagen And Astellas Announced Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival In Patients Treated with PADCEV And KEYTRUDA In First-Line Advanced Bladder Cancer
Charles Gross
-
Oct 22, 2023, 10:48AM
Genmab And Seagen Announced TIVDAK Significantly Prolonged Overall Survival In Patients with Recurrent Or Metastatic Cervical Cancer Compared With Chemotherapy In Global Phase 3 innovaTV 301 Trial
Charles Gross
-
Oct 22, 2023, 10:39AM
Thursday, October 19, 2023
Pfizer Secures Unconditional EU Antitrust Approval For $43B Seagen Deal
Benzinga Newsdesk
-
Oct 19, 2023, 10:49AM
Wednesday, October 18, 2023
Takeda Announces European Commission Approves ADCETRIS For The Treatment Of Adult Patients With Previously Untreated CD30+ Stage III Hodgkin Lymphoma In Combination With AVD
Happy Mohamed
-
Oct 18, 2023, 4:39PM
Truist Securities Reiterates Hold on Seagen, Maintains $229 Price Target
Benzinga Newsdesk
-
Oct 18, 2023, 1:16PM
Tuesday, October 17, 2023
Here's How Much $1000 Invested In Seagen 5 Years Ago Would Be Worth Today
Benzinga Insights
-
Oct 17, 2023, 2:30PM
Monday, October 16, 2023
Seagen To Highlight Overall Survival Data For PADCEV And TIVDAK During Presidential Symposium At ESMO Congress 2023
Benzinga Newsdesk
-
Oct 16, 2023, 8:08AM
Monday, October 09, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Oct 9, 2023, 1:35PM
Friday, October 06, 2023
How Is The Market Feeling About Seagen?
Benzinga Insights
-
Oct 6, 2023, 1:15PM
Thursday, October 05, 2023
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
Vandana Singh
-
Oct 5, 2023, 9:35AM
Friday, September 29, 2023
If You Invested $100 In This Stock 20 Years Ago, You Would Have $3,400 Today
Benzinga Insights
-
Sep 29, 2023, 1:00PM
Wednesday, September 27, 2023
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
Piero Cingari
-
Sep 27, 2023, 12:04PM
Seagen Unusual Options Activity
Benzinga Insights
-
Sep 27, 2023, 10:46AM
Monday, September 25, 2023
Truist Securities Reiterates Hold on Seagen, Maintains $229 Price Target
Benzinga Newsdesk
-
Sep 25, 2023, 8:31AM
Friday, September 22, 2023
Why Is Seagen Stock Trading Higher Today?
Vandana Singh
-
Sep 22, 2023, 11:05AM
Seagen shares are trading higher after the company and Astellas Pharma announced PADCEV and KEYTRUDA significantly improve overall survival and progression-free survival in patients with previously untreated advanced bladder cancer in pivotal Phase 3 EV-302 trial.
Benzinga Newsdesk
-
Sep 22, 2023, 9:21AM
Seagen And Astellas Pharma Announced PADCEV And KEYTRUDA Significantly Improve Overall Survival And Progression-Free Survival In Patients With Previously Untreated Advanced Bladder Cancer In Pivotal Phase 3 EV-302 Trial
Charles Gross
-
Sep 22, 2023, 5:04AM
Show more